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THERAPEUTIC POTENTIAL OF TARGETING THE ONCOFETAL ANTIGEN 
ROR1 
FERNANDA BEHZADI 
ABSTRACT 
 
 The increasing prevalence of drug resistant cancers to conventional therapies 
remains a major challenge in oncology, emphasizing the need for further research and 
treatment development. The receptor tyrosine kinase-like orphan receptor 1 (ROR1) 
presents as a particularly suitable target for cancer therapy, as this type I transmembrane 
protein is expressed during embryogenesis and up-regulated in various solid and 
hematological malignancies, but generally repressed in normal adult tissues. A growing 
cancer literature has established ROR1 as a contributor to cell metastasis and a survival 
factor for malignant cells, suggesting the therapeutic potential in targeting ROR1 for 
cancer therapy. The tumor-selective expression of ROR1 has encouraged investigation of 
novel ROR1-targeted therapies including monoclonal antibodies, small molecule 
inhibitors, and chimeric antigen receptor T-cells, and preclinical trials have supported 
their safety and efficacy in inducing tumor growth suppression. Despite these advances in 
therapeutics, the role of ROR1 in oncogenic signaling is not yet fully understood.  
Through a comprehensive examination of ROR1 literature, this review will examine the 
biology of ROR1 as it relates to tumor progression, and demonstrate the viability of 
current ROR1-targeted therapies. 
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INTRODUCTION 
 
 
 Receptor tyrosine kinase-like orphan receptors (ROR) are evolutionarily 
conserved, type I transmembrane proteins within the receptor tyrosine kinase (RTK) 
family. Both ROR1 and ROR2 are receptors for the Wnt5a ligand, which activates the 
non-canonical Wnt signaling pathway essential for the organization and orientation of 
cells during organogenesis (Dealy, Roth, Ferrari, Brown, & Kosher, 1993). RORs are 
indispensable for development, as genetic deletion of either gene leads to embryonic 
lethality and skeletal defects (Matsuda et al., 2001). In cancerous tissues, ROR1 and 
ROR2 are shown to be highly up-regulated, and thus correlated with an increased cancer 
aggressiveness (Daneshmanesh et al., 2008). Despite the important roles of ROR1 and 
ROR2 in developmental morphogenesis and cancer metastasis, their function and 
characterization in normal adult tissues are not well understood.  
 Similar to other RTKs, ROR1 and ROR2 are predominately expressed in the 
plasma membrane (Matsuda et al., 2001). Vertebrate ROR1 and ROR2 share similar 
domain architecture consisting of an extracellular immunoglobulin-like (Ig) domain at the 
amino-terminus, followed by a Frizzled-like cysteine-rich domain (CRD), and 
membrane-proximal Kringle domains (Matsuda et al., 2001). The CRD is particularly 
intriguing, as this domain is crucial in binding the Wnt5a ligand and initiating a 
proliferation pathway associated with regulating tumor growth (Mikels & Nusse, 2006). 
The intracellular regions are characterized by a tyrosine kinase (TK) domain, followed by 
two serine/threonine-rich domains (S/TRD1 and 2T), and a proline-rich domain (PRD) 
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(Masiakowski & Carroll, 1993). Comparative genomic studies have identified ROR 
orthologs across different species in addition to humans and mice, including fruit flies 
(Drosophila melanogaster), roundworms (Caenorhabditis elegans), and sea slugs 
(Aplysia californica) (Katoh & Katoh, 2005). Although the CRD, Kringle, and TK 
domains are conserved in all ROR orthologs, it important to note the differences in 
cytosolic domains across the various species (Figure 1).  
 
Figure 1. Structure of ROR orthologs across different species. RORs are 
evolutionarily conserved proteins, with ROR orthologs identified in vertebrates 
(ROR1/ROR2), Drosophila melanogaster (ROR), Aplysia california (ROR), and 
Caenorhabditis elegans (CAM-1). The extracellular domain is above and the intracellular 
domain is below the double line representing the plasma membrane. Taken from 
(Rebagay, Yan, Liu, & Cheung, 2012).  
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 Interestingly, the functionality of the TK domain has been the subject of 
speculation. Previous studies have proposed that ROR1 lacks the strong autocatalytic 
activity that is otherwise established in ROR2 (Gentile, Lazzari, Benvenuti, Trusolino, & 
Comoglio, 2011). More recent studies, however, have shown that the ROR1 kinase 
activity was sufficient enough to phosphorylate the proto-oncogene c-Src in the NIH3T3 
fibroblast cell line, indicating that the ROR1 TK domain is indeed catalytically active 
(Yamaguchi et al., 2012). Despite conflicting results, current literature has now shifted 
the focus onto the extracellular Wnt-binding CRD. A recent study in primary B-cell 
chronic lymphocytic leukemia (CLL) cells illustrated the importance of the CRD in 
binding Wnt5a and its effects on disease progression. Exogenous treatment of CLL cells 
with Wn5a induced the oligomerization of ROR1 with ROR2, which in turn activated 
Rho proteins that enhanced CLL cell proliferation and chemotaxis (Yu et al., 2015). This 
study, along with other ROR cancer literature, contribute to the rationale for targeting 
ROR1 and ROR2 to suppress tumor growth and proliferation. For the purpose of this 
literature review, the remainder of the focus will be primarily on the oncogenic ROR1 
protein. 
 
Specific Aims 
 Current cancer literature has established ROR1 as a marker for tumorigenesis. 
Unfortunately, our understanding of ROR1 in human malignancy and normal tissues is 
not entirely concrete and will require continued study. However, there is therapeutic 
potential in targeting ROR1, which presents the basis of this review. Thus, this paper will 
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focus on reviewing primary literature in order to identify different signaling mechanisms 
and methods that target ROR1, demonstrate why inhibition of ROR1 is appropriate for 
improving conventional therapeutics, assess differences and inconsistencies with study 
design and analysis, and promote future development of ROR1 therapy. 
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Figure 2. Schematic overview of ROR1 signaling pathways. ROR1-mediated signaling 
has been reported in a number of different cancers and cell lines. This diagram provides 
an overview of the different pro-survival mechanisms implicated with ROR1, and will be 
further discussed throughout this review.  
 
Functionality of ROR1 in Embryogenesis  
 The importance of ROR1 in embryonic development has been extensively 
examined by in situ hybridization and mutant knockout murine models. mROR1 
expression is generally observed in derivatives of all three germ layers, most prominently 
in cephalic mesenchyme and neural crest cells of embryos (Figure 3A-C; Matsuda et al., 
2001).  In the developing limbs, mROR1 expression is reportedly observed as early as 
day 9.5 of embryonic development (E9.5) (Matsuda et al., 2001). As limb development 
proceeds, mROR1 becomes largely localized to the anterior and posterior regions of the 
limb mesenchyme, observed in E12.5 and on (Figure 3D-E; Matsuda et al., 2001). At 
later stages, mROR1 becomes highly implicated with skeletal and cardiorespiratory 
development, with expression observed in organs including, but not limited to, the heart, 
lung, and the eye (Figure 3F-H, respectively; Matsuda et al., 2001). 
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Figure 3. mROR1 expression patterns during early embryonic development. 
Developmental mouse stages and expression are analyzed by in situ hybridization. 
mROR1 is detected in early stages of embryogenesis (A). At E8.5, mROR1 is highly 
observed in neural crest cells of the cephalic region (B) and developing face (C). In the 
developing limbs, mROR1 becomes localized to the anterior and posterior regions by 
E12.5 (D), and in the interdigital regions at E13.5 (E). Expression of mROR1 in neural 
crest cell derivatives are observed in the developing heart, lung, and eye (F, G, H 
respectively) by E13.5. le, lens; lv, left ventricle; nc, neural crest; pa, pharyngeal arches. 
Taken from (Matsuda et al., 2001). 
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The implications of ROR1 in development are further emphasized by the respiratory 
dysfunction observed in mutant ROR1 knockout mice. This study demonstrated that 
mRor1−/− mice could not survive beyond 24 hours after birth, and postmortem 
histological analysis attributed the lack of viability to the mutated alveolar air sacs and 
pulmonary bleeding observed (Nomi et al., 2001). A more recent study underscored the 
function of ROR1 in skeletal development, as ROR1 mutant embryos demonstrated 
severe skeletal defects prior to birth (Lyashenko et al., 2010). Postnatal results also 
indicated skeletal growth retardation and urogenital abnormalities in mRor1−/− mice, 
impacting their life expectancy and female infertility (Lyashenko et al., 2010). Overall, 
ROR1 function is not well characterized in adult tissue since genetic deletion results in 
significantly impaired growth and embryonic lethality. A recent study, however, sought 
to characterize the role of ROR1 in adult mice, particularly in regulating muscle 
regeneration and satellite cells (SCs) proliferation following an injury (Kamizaki et al., 
2017). After a cardiotoxin-induced muscle injury, Kamizaki et al. (2017) quantified the 
relative expression of ROR1 mRNA and proportion of SCs at various time points in 
control mice and ROR1 conditional knock-outs (cKOs). Results showed a concurrent 
increase in ROR1 mRNA and SCs at day 3 in control mice, but not in ROR1 cKOs, 
indicating that ROR1 may play a critical part in regulating the proliferation of SCs in 
adult mice following tissue injury (Kamizaki et al., 2017). Although these results support 
the involvement of ROR1 in adult tissue, the mechanisms of action remain unclear and 
are still being investigated.  
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Anomalous Expression in Cancer 
 While ROR1 expression is largely embryonal, there is widespread evidence to 
suggest high levels of ROR1 to be associated with hematological malignancies and solid 
tumors. Initial reports suggested ROR1 as a highly expressed cell surface antigen in CLL, 
while completely absent in healthy peripheral blood mononuclear cells (PBMC) (Baskar 
et al., 2008).  Further studies confirmed ROR1 expression in additional hematological 
malignancies such as mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), 
follicular lymphoma (FL), myelomas, acute lymphoblastic leukemia (ALL), diffuse large 
B-cell lymphoma (DLBCL) and myeloid leukemias (Daneshmanesh, Porwit, et al., 
2012). Of particular interest is the correlation between ROR1 expression and disease 
progression. A transcriptome analysis of 1568 CLL patients revealed that CLL cases that 
expressed high-level ROR1 had a more aggressive disease progression and a shorter 
overall survival than patients with low-level ROR1, suggesting the use of ROR1 as a 
prognostic marker (Cui et al., 2016).  
 An immunohistochemistry (IHC) analysis of a variety of solid cancers revealed 
the proportion of each tumor type with a strong ROR1 positive staining (staining on 
>50% of tumor cells), weak to moderate positive staining (staining on ≤ 50% of tumor 
cells) or negative staining (no ROR1-mAb specific staining on all tumor cells) (Figure 4; 
Zhang et al., 2012). Among the ROR1 positive samples were ovarian cancers (78/144), 
skin cancers (49/55), pancreatic cancers (45/57), colon cancers (63/110), lung cancers 
(52/58), adrenal cancers (10/12), uterus cancers (28/29), and testicular (35/48) and 
prostate cancers (19/21) (Zhang et al., 2012).  
 9 
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Figure 4. ROR1 expression in cancers. Top panel: Formalin-fixed, paraffin-embedded 
(FFPE) sections of normal and neoplastic tissues were stained with a high-affinity ROR1-
mAb (namely 4A5) or control (IgG2b). Positive 4A5 staining is shown in red, and 
nuclear staining is shown in blue. Bottom panel: The intensity of staining for each tumor 
type is represented by the shading in the bar graph, and the number of samples is 
indicated in parentheses. The shading represents the proportion of each tumor type 
stained by 4A5, separated by strong (staining on >50% of tumor cells), moderate 
(staining on ≤ 50% of tumor cells) or negative (no 4A5 staining). Taken from (Zhang et 
al., 2012). 
 
This study also reported that primary cancers with high levels of ROR1 were 
significantly more likely to express phosphorylated protein kinase B (p-Akt) and 
phosphorylated cAMP (p-cAMP), both of which are highly implicated with promoting 
tumor growth and proliferation. Indeed, these results allude to an incredible potential in 
suppressing tumor growth by targeting ROR1 and its downstream targets. It would be of 
interest to expand upon these findings, and identify an association between the expression 
of ROR1, p-Akt, and p-cAMP with disease progression in order to characterize a 
prognostic marker for each solid tumor type. Zheng et al. (2016), for instance, have been 
able to establish a relationship between ROR1 expression and the clinicopathological 
features of lung adenocarcinoma (ADC) patients. An IHC analysis of 232 lung ADC 
patients revealed that high ROR1 expression was most closely associated with advanced 
stages of lung ADC (stage III and IV) (Zheng et al., 2016). Notably, 57.9% of patients at 
stage III-IV exhibited high expression of ROR1 protein, whereas only 21.3% of patients 
at stage I-II showed high ROR1 expression (Zheng et al., 2016). Survival analysis also 
indicated a linear relationship between high ROR1 expression and worse overall survival 
(Zheng et al., 2016). Taken together, this novel data supports ROR1 as a prognostic 
marker for lung ADC patients. 
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 In order to further characterize ROR1 expression in human cancer, genomic data 
was extrapolated and analyzed from The Cancer Genome Atlas (TCGA) and the Cancer 
Cell Line Encyclopedia (CCLE). Notably, both pan-cancer TCGA analysis and CCLE 
revealed significant gene expression heterogeneity across all tumor types (Cerami et al., 
2012; Gao et al., 2013; Barretina et al., 2012). Additionally, both datasets indicated that 
somatic mutations and copy number variations occur at low frequencies across cancer 
types (Cerami et al., 2012; Gao et al., 2013; Barretina et al., 2012). Current genomic data 
does not support ROR1 gene alteration as a major contributor to cancer, and the observed 
gene expression heterogeneity within and across cancer types suggest that multiple 
mechanisms contribute to its over-expression.  
Collectively, the results highlight the potential in targeting the tumor-selective 
ROR1. Despite being generally absent, there have been recent studies to indicate ROR1 
expression in healthy adult tissue. Initial studies investigating ROR1 expression in 
normal tissue have indicated that while ROR1 is down-regulated after development, low 
levels remain in a subset of non-neoplastic human B-lymphocyte precursors typically 
found in the bone marrow of healthy infants (Broome, Rassenti, Wang, Meyer, & Kipps, 
2011). However, the characterization of cell surface ROR1 in normal adult tissue 
continues to be investigated. Previous IHC analysis of FFPE adult tissues revealed 
primarily cytoplasmic ROR1 expression, with the exception of plasma membrane 
staining found on adipocytes of the bone marrow (Dave et al., 2012). These results were 
contradictory to the cell surface pattern typically observed of ROR1, warranting the need 
for further development of a more specific ROR1 antibody. Balakrishnan et al. (2016) 
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evaluated previously tested ROR1-targeting antibodies, and found that the majority 
lacked sensitivity to endogenously expressed cell surface ROR1 in FFPE tissues. This 
finding prompted the development of a highly specialized murine monoclonal antibody 
(mAb) 6D4, designed to detect endogenous ROR1 with greater sensitivity and less cross-
reactivity than previous mAbs used in IHC (Balakrishnan et al., 2016). Contrary to 
previous reports, the results indicated that ROR1 is highly expressed on several healthy 
tissues, including the parathyroid, adipose, pancreatic islets, regions of the esophagus, 
stomach, and duodenum, justifying the major concern of toxicity to normal tissues 
(Balakrishnan et al., 2016).  
 
ROR1 in Signal Transduction 
 ROR1 enhances tumor cell growth and metastasis by mediating pathways 
implicated with cancers, such as PI3K/Akt/mTOR, EGFR signaling, and the p38 
signaling pathway. Conversely, targeting ROR1 results in the down-regulation of these 
pro-survival signals, inducing apoptosis and impairing malignant cell growth. These 
examples of ROR1-mediated signaling have been observed in various cell lines and 
cancers. 
 The PI3K/Akt/mTOR signaling pathway is frequently dysregulated in certain 
cancers and plays a critical role in tumorigenesis (Samuels et al., 2004). In the context of 
CLL, the catalytic subunit of PI3K p110 (PI3Kδ) has shown to be constitutively activated 
by ROR1, thus phosphorylating Akt and subsequent downstream targets such as mTOR. 
(Daneshmanesh et al., 2014). The p85 regulatory subunit of PI3K is especially critical to 
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the activation of PI3K, as p85 contains Src homology-2 (SH2) domains that mediate the 
interaction with phosphorylated ROR1, and consequential activation of PI3K 
(Yamaguchi et al., 2012). Previously, Daneshmanesh et al. (2014) demonstrated that the 
anti-CRD ROR1 mAb induced direct apoptosis of human CLL cells, while mAbs 
targeting the Ig-domain failed to do so. In order to further understand the therapeutic 
implications of targeting ROR1 and its effect on the PI3K/Akt/mTOR pathway, the same 
group treated CLL cells with the anti-CRD ROR1 mAb. Immunoblot analysis indicated a 
significant dephosphorylation of ROR1 and PI3K/Akt/mTOR pathway signaling 
molecules following anti-CRD ROR1 mAb treatment, in comparison to a control mAb 
(Daneshmanesh et al., 2014). Furthermore, the anti-CRD ROR1 mAb was able to induce 
significant dephosphorylation of the oncogenic transcription factor, CREB 
(Daneshmanesh et al., 2014). Although a significant association has been made between 
ROR1 expression and CREB-enhanced tumor growth, the role of CREB in the apoptotic 
cascade has not yet been confirmed (Zhang et al., 2012). 
Since the apoptosis of CLL cells was preceded by the dephosphorylation of ROR1 
and associated signaling molecules found in Figure 4, the authors were able to attribute a 
major association between ROR1 and the downstream signaling of the PI3K/Akt/mTOR 
pathway. More specifically, the authors proposed that the binding of the anti-CRD ROR1 
mAb to ROR1 dephosphorylated the p85 regulatory subunit of PI3K, preventing the 
activation of the PI3K catalytic subunit and any subsequent downstream signal 
transmission (Daneshmanesh et al., 2014). Taken together, these results suggest an 
association of ROR1 with PI3K signaling, demonstrating the potential of ROR1-targeting 
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therapies in inhibiting this tumorigenic pathway and preventing downstream signaling of 
PI3K, ultimately inducing apoptosis of CLL cells.  
 
Figure 5. Relative intensity of tumor signaling molecules following anti-CRD ROR1 
mAb treatment. CLL cells were treated with an anti-CRD ROR1 mAb, and measured 
for relative intensity of phosphorylated proteins to total proteins after 2h of incubation, 
indicated by the black bars. The white bar represents relative intensity of the proteins 
without the anti-CRD ROR1 mAb treatment. P values indicate statistical significance. 
Taken from (Daneshmanesh et al., 2014). 
 
Similar results were observed by a different cell model, in which the human lung  
 
ADC cell line (PC9) and non-small cell lung cancer (NSCLC) cell line (NCI-H1975)  
 
were transfected with ROR1-targeting siRNA sequences. Both ROR1-positive  
 
(ROR1+) cell lines, PC9 and NCI-H1975, silenced for ROR1 demonstrated remarkable 
levels of apoptosis compared to the same cell lines treated with the control non-silencing 
siRNA (18.4% vs 3.5%, 16.8% vs 4.6%, respectively). Furthermore, immunoblot  
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analysis of PC9 and NCI-H1975 treated with ROR1-targeting siRNA (siROR1) showed a 
significant reduction in p-Akt and p-mTOR, both features of activated Akt and mTOR, 
suggesting that ROR1 is a survival factor of the PI3K/Akt/mTOR signaling pathway. 
siROR1 treatment also indicated a reduction in p-PTEN, a tumor suppressor phosphatase 
with oncogenic properties when phosphorylated (Liu et al., 2015).  
 
Figure 6. ROR1 regulates the PI3K/Akt/mTOR signaling pathway. PC9 and NCI-
H1975 cells were treated for 72h with ROR1 siRNA (siROR1) or control siRNA 
(siControl). The following molecules were examined: p-Akt at Ser-473, p-mTOR at Ser-
2448, and p-PTEN at Ser-380/Thr-382/383. The decrease in p-Akt, p-mTOR, and p-
PTEN indicates that the activation of this signaling pathway is associated with ROR1 
expression. Taken from (Liu et al., 2015). 
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In addition to the pro-survival PI3K/Akt/mTOR pathway, ROR1 has shown to 
mediate EGFR signaling in ADCs. Microarray analysis of a human peripheral lung 
epithelial cell line (HPL1D) revealed that ROR1 was a direct transcriptional target for 
NKX2-1, an oncogene essential for EGFR mutations in lung ADC (Yamaguchi et al., 
2012). As expected, siROR1 treatment inhibited ADC growth in vitro and significantly 
reduced in vivo xenograft tumor growth, supporting the involvement of ROR1 in NKX2-
1-mediated survival signaling (Yamaguchi et al., 2012).  
This study also examined the effect of targeting ROR1 on other lung ADC 
survival signals, particularly ErbB-3 and c-Src. ErbB-3, a unique kinase-impaired 
member of the EGFR family, has been reported in various malignancies (Jaiswal et al., 
2013). In the context of lung ADC, ErbB-3 is shown to heterodimerize with EGFR and 
activate PI3K, promoting the oncogenic PI3K/Akt/mTOR signaling pathway (Engelman 
et al., 2005). The question of how ROR1 expression contributes to EGFR signaling in 
lung ADC was explored using EGF-treated NCI-H1975 cells. Interestingly, ROR1 bound 
to EGFR upon EGF treatment, consequently activating EGFR to couple with ErbB-3 and 
thus increase PI3K signaling (Yamaguchi et al., 2012). In line with the ROR1-induced 
activation of ErbB-3, ROR1 knockdown significantly reduced the binding of PI3K to 
ErbB-3, indicating that ROR1 was able to sustain pro-survival signaling through ErbB-3 
(Yamaguchi et al., 2012). Conversely, ROR1 knockdown also induced the 
phosphorylation of the pro-apoptotic signaling molecule p38, suggesting that ROR1 
normally represses those pro-apoptotic effects (Yamaguchi et al., 2012).  
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The proto-oncogene c-Src was also identified as a downstream molecule in 
ROR1-mediated signaling. Following c-Src siRNA treatment in xenografts 
overexpressing ROR1, the authors determined that tumor growth and signaling were 
inhibited in vivo, suggesting the importance of c-Src as a downstream ROR1 effector 
(Yamaguchi et al., 2012). Additionally, siROR1 treatment revealed a very similar 
phenotype to c-Src siRNA treatment in vivo, with respect to inhibiting tumor growth and 
signaling (Yamaguchi et al., 2012). Collectively, these results identify ROR1 as playing a 
critical role between pro-survival and pro-apoptotic signaling. 
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Figure 7. NKX2-1-induced ROR1 mediates the balance between pro-apoptotic p38 
signaling and the pro-survival PI3K/Akt/mTOR pathway in lung ADC. The 
transcription factor NKX2-1, important for normal lung function, activates expression of 
ROR1 in lung ADC. In turn, ROR1 associates with EGFR and leads to the 
phosphorylation of ErbB-3, a member of the EGFR family implicated with metastasis 
and tumor growth. NKX2-1-induced ROR1 is also shown to mediate the survival signal 
c-Src, while inhibiting the pro-apoptotic effects of the p38 signaling cascade. Taken from 
(Yamaguchi et al., 2012) 
 
Rationale for Targeting ROR1 
 ROR1 presents as a promising therapeutic target for anticancer therapy. By 
exploiting the unique expression profile, future research can focus on minimizing on-
target off-tumor toxicities by optimizing current ROR1-targeting therapies. As previously 
discussed, the definitive expression of ROR1 in normal tissues is still under debate, 
which some may argue as problematic to ensuring safety. Despite the potential for 
toxicity, this review will highlight the therapeutic implications associated with current 
ROR1-targeting therapies. Additionally, published studies have supported the correlation 
between ROR1 expression and disease progression, indicating the possible use of ROR1 
as a prognostic marker in cancers such as ovarian cancer, pancreatic cancer, CLL, and 
lung ADC (Zhang et al., 2014; Xu, Shen, Xu, Wang, & Ni, 2018; Hojjat-Farsangi et al., 
2013; Zheng et al., 2016). 
 Despite the initial effectiveness of current cancer therapies, drug resistance 
persists as a critical challenge. For instance, it has been reported that 10% of NSCLC 
patients harboring an EGFR mutation in exon 19 or 21 presented with primary tyrosine 
kinase inhibitor (TKI) resistance, while another 50% of patients acquired a secondary 
resistance within 9-12 months after starting the TKI therapy (Liu et al., 2015). In the 
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context of MCL, drug resistance to Ibrutinib has also impaired patient response to 
treatment. Acquired resistance to Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor 
designed to target the B-cell antigen receptor (BCR)-signaling pathway crucial for B-cell 
malignancies, underscores the importance of investigating a new generation of cancer 
therapeutics (Chiron et al., 2015). Targeting ROR1 has presented as a viable strategy to 
overcome resistance, especially since the down-regulation of ROR1 augmented drug 
sensitivity for BCR pathway inhibitors (Figure 8; Karvonen et al., 2017). The efficacy of 
combining ROR1 therapy with BCR inhibitors will be further explored in this paper.  
 
Figure 8. The synergistic effect of co-targeting ROR1 and the BCR-signaling 
pathway in the MCL model. The nuclear factor NF-κB pathway is shown to be a 
downstream effector of both ROR1 and the BCR-signaling pathway. Aberrant NF-κB 
activation has been associated with promoting cancer cell survival and metastasis. Thus, 
ROR1-targeting therapies presents as a possible candidate for augmenting the therapeutic 
potential of BTK inhibitors in MCL. Taken from (Karvonen et al., 2017). 
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Taken together, the presented data provides strong evidence to support the 
rationale for targeting ROR1. As a result, the remainder of the paper will concentrate on 
published data regarding ROR1-targeting therapies, in order to contribute to a greater 
understanding of the oncofetal protein ROR1 as well as emphasize the significance in 
optimizing current therapy for future use. 
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PUBLISHED STUDIES: 
ROR1- TARGETED ANTICANCER THERAPIES 
 
ROR1 presents as a promising target for cancer therapy, and strategies such as mAbs, 
antibody-drug conjugates (ADC), small molecule inhibitors (SMI), and chimeric antigen 
receptor T (CAR-T) cells are currently being explored for therapeutic utility. The 
following sections discuss the published data in the context of hematological and solid 
cancers, in order to assess safety and efficacy of ROR1-targeted therapies.  
 
Cirmtuzumab  
The earliest report of ROR1-targeting mAbs were generated by a chimeric 
rabbit/human Fab library and screened for their ability to bind to the extracellular 
domains of hROR1 and mROR1 in CLL cells (Yang et al., 2011). This study paved the 
way for the development of mAbs specific against the Frizzled-like CRD and Kringle 
domain, which proved to be the most effective in inducing apoptosis of CLL cells 
(Daneshmanesh, Hojjat-Farsangi, et al., 2012). Currently, the mechanisms of action for 
anti-ROR1 mAbs are not well understood. However, it is known that the binding of the 
mAb to the extracellular domains of ROR1 initiates a rapid dephosphorylation that 
precedes apoptosis of CLL cells (Hojjat-Farsangi et al., 2013). Therefore, it is possible 
that ROR1 phosphorylation may be ligand dependent, and the anti-ROR1 mAb may 
prevent binding of the ROR1 ligand.  
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Although several anti-ROR1 mAbs have been investigated, only cirmtuzumab has 
entered phase I/II clinical trial for the treatment of patients with relapsed or refractory 
CLL (clinicaltrials.gov, NCT02222688). Cirmtuzumab (formerly known as UC-961) is a 
first-in-class, humanized mAb designed to bind with high affinity to a particular 
extracellular epitope of human ROR1, and thus block the binding of the Wnt5a ligand to 
inhibit cancer growth and metastasis pathway ROR1+ malignancies (Figure 9; 
“Cirmtuzumab,” n.d.). In vitro studies conducted on the ROR1+ CLL cell line MEC1 
showed high levels of activated Rac1 and RhoA, both of which are important for tumor-
cell chemotaxis and proliferation (Yu et al., 2015). Treatment with cirmtuzumab inhibited 
these tumorigenic effects and blocked the Wnt5a-induced activation of guanine exchange 
factors (GEFs), RhoA, and Rac1, causing tumor cell death by apoptosis (Figure 9; Yu et 
al., 2015). This propelled in vivo investigation on immunodeficient mice engrafted with 
ROR1+ MEC1 cells, demonstrating that cirmtuzumab was able to successfully inhibit the 
growth of malignant CLL cells (Yu et al., 2015). In addition to the anti-leukemic results, 
no cytotoxicity or adverse events were observed when administered to healthy rodents 
and primates (Choi et al., 2015). 
 
 
 
 23 
 
 
 24 
Figure 9. Cirmtuzumab binds to ROR1 and blocks the proliferative Wnt5a 
pathway. In the top panel, ROR1 acts as a binding site for the tumor growth factor 
Wnt5a and recruits guanine exchange factors (GEF), which activates a signaling cascade 
responsible for tumor growth and metastasis. Treatment with cirmtuzumab inhibited 
these effects by blocking the binding site for Wnt5a. Taken from 
(http://www.oncternal.com/Pipeline/Cirmtuzumab). 
 
Recent phase I trials conducted by Choi et al. (2018) reaffirmed cirmtuzumab 
efficacy, safety, and tolerability in CLL patients receiving four biweekly infusions with 
doses ranging from 0.015 to 20 mg/kg. Patients were assessed for levels of 
phosphorylated HS1 (pHS1) and activated RhoA, both viable indicators of ROR1 
signaling in leukemia cells. Reductions in the ratios of pHS1/HS1, as well as activated 
RhoA, were observed within 24 hours after the first infusion of cirmtuzumab, and despite 
reaching pre-treatment levels months after administration, pHS1/HS1 levels again 
decreased after re-treatment. A dose-dependent relationship was also observed, as 
patients that received cirmtuzumab at doses ≥ 2 mg/kg had a 33% reduction in surface 
expression of ROR1, while cirmtuzumab administered at lower doses showed minimal to 
no reductions in surface ROR1 (Choi et al., 2018).  There were no drug-related adverse 
events or dose-limiting toxicities, which remained consistent with pre-clinical studies and 
encouraged further research in combination with other anti-leukemia therapies.  
Due to the promising in vitro and in vivo results observed with cirmtuzumab as a 
monotherapy (Yu et al., 2015), several studies have now assessed the use of cirmtuzumab 
in combination with other cancer therapeutics. The following study by Yu et al. (2016) 
explored Ibrutinib, a BTK inhibitor that blocks BCR signaling and prevents the growth of 
malignant B cells, as an effective candidate for use in combination with cirmtuzumab. 
Despite having significant clinical benefit, ibrutinib alone cannot suppress CLL, likely 
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because of the proliferative effects of the ROR1/Wnt5a pathway that are unaffected by 
BTK inhibitors. In vivo tests of CLL patient-derived xenografts revealed that after 7 days, 
the percentage of CLL cells present following cirmtuzumab and ibrutinib treatment was 
47.7% and 59.3% respectively. However, when treated with both cirmtuzumab and 
ibrutinib, only 13.3% of harvested cells were CLL cells, indicating that the combination 
therapy was significantly more effective in clearing CLL cells in vivo (Figure 10). 
Further in vivo analysis showed that the CLL xenografts treated with the cirmtuzumab 
and Ibrutinib combination had significantly smaller spleens and splenocyte/leukemia cell 
proportions in comparison to their counterparts (Yu et al., 2016).  
 
 
Figure 10. Treatment effect of cirmtuzumab and/or ibrutinib in CLL patient-
derived xenografts. The percentage of CLL cells collected among harvested cells post-
treatment are represented by each bar, with treatment dosages indicated below. *** 
represents P<0.001, **** represents P<0.0001. Taken from (Yu et al., 2016).  
 
The synergistic effects of cirmtuzumab and ibrutinib was also confirmed in the 
context of mantle cell lymphoma (MCL). In vitro use of this combination therapy on 
MCL cells revealed that cirmtuzumab, but not ibrutinib, could block the ROR1-
dependent signaling-pathway important for cancer cell proliferation and survival (Yu et 
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al., 2018), similar to the mechanism of action demonstrated in Figure 9. These results 
indicate the therapeutic potential of using ibrutinib and cirmtuzumab concurrently to 
target independent signaling pathways and thus improve lymphoma treatment.  
 
Antibody-Drug Conjugates 
ROR1 presents as a viable antibody-drug conjugate (ADC) target. ADCs are an 
emerging class of biopharmaceutical drugs with a promising future in the treatment of 
ROR1+ malignancies. ADC therapy combines a highly selective antibody moiety to a 
potent small molecule toxin via a stable linker, and binds to a tumor-associated antigen in 
order to eliminate cancer cells (Hellmann et al., 2018). Upon binding to ROR1, an anti-
ROR1 mAb such as cirmtuzumab is readily internalized and absorbed, which 
subsequently allows the release of cytotoxic drugs into the cancer cell and induces 
apoptosis (Baskar et al., 2008). By exploiting the internalization rate of anti-ROR1 mAbs, 
ADC presents as a therapeutic treatment in preclinical ROR1 models.  
In addition to its high affinity and specificity for ROR1, cirmtuzumab has 
exhibited a greater rate of internalization by malignant ROR1+ cells compared to other 
anti-ROR1 mAbs (Cui et al., 2013). In vitro studies showed that cirmtuzumab vedotin, a 
cirmtuzumab-linker-monomethyl auristatin E (MMAE) ADC that allows for ROR1-
targeted release of toxic MMAE, was selectively cytotoxic against ROR1+ 
adenocarcinoma cell lines of the breast and pancreas, while normal ROR1- cell lines 
remained intact (Cui et al., 2013). The paper also presented in vivo studies demonstrating 
that ADC-treated immunodeficient mice engrafted with a ROR1+ MCL cell line (JeKo-1) 
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had a five-fold decrease in leukemic cells compared to the cohort treated with control IgG 
(Cui et al., 2013). Collectively, these results showed that the effects of cirmtuzumab may 
be enhanced when linked with a drug conjugate.   
Using the same principle, Mani et al. (2014) utilized an anti-ROR1 mAb (2A2-
IgG) for targeted delivery of a novel non-immunosuppressive FTY720 derivative, OSU-
2S, with known cytotoxicity against malignant B cells. To address the possibility of 
OSU-2S toxicity to normal B cells, the authors utilized liposomal immunonanoparticles 
(ILPs) to encapsulate and deliver the drug, selectively targeting leukemic B cells while 
sparing normal B cells. 2A2-IgG was internalized by CLL cells at a rate almost three-
folds greater than anti-CD19 and anti-CD37 mAbs, emphasizing the benefit of linking the 
toxin with an mAb specific to ROR1, a target primarily restricted to malignant CLL B 
cells (Mani et al., 2014). Utilizing the ROR1 specific 2A2-IgG is particularly 
advantageous given its specificity to leukemic cells but not healthy donor B cells. Other 
B cell targeting mAbs such as CD19 or CD20 pose a threat to healthy B cells, especially 
since these cell surface molecules are expressed in both healthy and neoplastic B cells 
(Mani et al., 2014). 
The success of 2A2-IgG-ILP internalization by leukemic cells prompted the in 
vitro treatment of OSU-2S encapsulated in 2A2-IgG-ILP (fully known as 2A2-OSU-2S-
ILP), which resulted in a significant 60% decrease in CLL cells (Mani et al., 2014). The 
benefits of utilizing an anti-ROR1 mAb in vitro is further elucidated when comparing the 
2A2-OSU-2S-ILP results to its non-ROR1 targeting counterpart (IgG-OSU-2S-ILP), in 
which only a 25% decrease in CLL cells was observed (Mani et al., 2014). In vivo 
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evaluation of 2A2-OSU-2S-ILP in mice engrafted with ROR1+ leukemic splenocytes 
revealed cytotoxicity specific to malignant cells, as well as prolonged survival rates in 
2A2-OSU-2S-ILP treated mice (Figure 11; Mani et al., 2014). These results remained 
consistent with the previously discussed ROR1-targeting ADC study. 
 
Figure 11. Survival rates of ROR1 targeted OSU-2S delivery in a hROR1+ CLL 
mouse model. Kaplan-Meier analysis demonstrates the survival of engrafted mice 
following treatment as a function of time. Treatment with the ROR1 specific OSU-2S 
drug, represented as 2A2-OSU-2S-ILP, showed the longest rate of survival in the CLL 
model due to its specificity for ROR1+ malignant B cells. IgG-OSU-2S-ILP represents 
non-ROR1 targeting mouse IgG, 2A2-Empty-ILP represents an empty liposome, and 
OSU-2S-LP represents the liposomal packaged OSU-2S. Sample size is indicated in 
parentheses. Taken from (Mani et al., 2014). 
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KAN0439834 
 KAN0439834 is a promising SMI that suppresses tumor growth by targeting the 
TK domain of ROR1, consequently inducing apoptosis of tumor cells (Daneshmanesh et 
al., 2018). This in vitro study was performed on a panel of eight human pancreatic 
carcinoma (PC) cell lines and compared the antitumor properties of KAN0439834 to 
gemcitabine (nucleic acid synthesis inhibitor), erlotinib (EGFR inhibitor), ibrutinib (BTK 
inhibitor), and a mROR1 mAb generated against the extracellular CRD domain of ROR1. 
Evidence showed a significant induction of apoptosis across all pancreatic cancer cell 
lines when incubated with KAN0439834, with the PaCa-2 cell line demonstrating the 
highest rate of apoptosis (82%) compared to the apoptosis induced by anti-ROR1 mAb 
(35%) (Daneshmanesh et al., 2018). Additionally, KAN0439834 caused complete 
dephosphorylation of the TK domain in a dose-dependent manner, compared to the 50% 
decrease in phosphorylated ROR1 induced by the anti-ROR1 mAb, even at its optimal 
cytotoxic dose. As expected, gemcitabine, erlotinib, and ibrutinib failed to induce any 
ROR1 dephosphorylation (Daneshmanesh et al., 2018). The paper further assessed the 
effects of KAN0439834 on ROR1 associated signaling molecules, and proteins levels 
showed that KAN0439834 was able to inhibit LRP6 (a co-receptor for ROR1), c-Src, 
CREB, PI3K, Akt, and mTOR phosphorylation – all of which are implicated with tumor 
cell proliferation (Daneshmanesh et al., 2018). 
This study, consistent with other ROR1 combination therapy studies, revealed a 
clear additive effect when combining gemcitabine, erlotinib, and ibrutinib with 
KAN0439834. It is postulated that these additive results may be partly explained by the 
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complementary mechanisms of action, indicated by the ability of KAN0439834 to inhibit 
ROR1 phosphorylation but not EGFR and BTK, the respective targets of erlotinib and 
ibrutinib (Daneshmanesh et al., 2018). As previously discussed, there is an obvious 
therapeutic benefit in targeting ROR1 simultaneously with inhibition of BCR signaling. 
Further studies demonstrated that KAN0439834 induced a statistically significant 
dose-dependent dephosphorylation of ROR1 in immunodeficient mice xenografted with 
human CLL cells (Hojjat-Farsangi et al., 2018). Similar to the results indicated in the 
pancreatic cancer cell line, KAN0439834 was able to dephosphorylate the same ROR1 
associated signaling molecules in CLL cells (Hojjat-Farsangi et al., 2018). In both the PC 
and CLL cell lines, ROR1 and its co-receptor LRP6 were shown to heterodimerize. 
Interestingly, the heterodimerized ROR1/LRP6 complex did not dissociate after 
incubation with KAN0439834 in the pancreatic cell line, whereas a dissociation was 
observed in the CLL cells (Hojjat-Farsangi et al., 2018). However, the relationship 
between ROR1 and LRP6 heterodimerization in the apoptotic cascade is not well 
understood. 
 
Chimeric antigen receptor-engineered T cells 
In contrast to the specific binding of mAbs and SMIs to the target, T cells have the 
capability to proliferate and lyse cancer cells directly. As a result, Hudecek et al. (2010) 
engineered human cytotoxic (CD8+) T cells to express a chimeric antigen receptor (CAR) 
specific to ROR1, allowing the modified T cell to target malignant ROR1+ B cells while 
sparing normal B cells. After binding to the targeted ROR1 antigen, the CAR-T cell 
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proliferates and destroys targeted cells by mechanisms including direct lysis to cells and 
stimulating secretions factors (i.e. cytokines) (Hudecek et al., 2010). 
The authors demonstrated that CD8+ ROR1-CAR T cells derived from both healthy 
individuals and CLL patients were able to efficiently lyse primary CLL cells at 
equivalent levels. Unlike the ROR1-CAR T cells, CD20-CAR expressing T-cells did not 
spare normal B-cells, especially given the ubiquitous expression of CD20 on all B cells 
(Hudecek et al., 2010). Further comparisons showed that patient and healthy donor 
derived CD8+ ROR1-CAR T cells produced comparable levels of effector cytokines 
(IFN-γ, TNF-α, and IL-2) and proliferated at equivalent rates in response to ROR1-
expressing tumor B cells (Hudecek et al., 2010). To address whether the in vitro success 
of the ROR1-CAR T cells would reflect the same improvement in anti-tumor activity in 
vivo, Hudecek et al. (2013) treated immunodeficient xenograft models engrafted with the 
ROR1+ MCL cell line JeKO-1, and compared ROR1-CARs of different affinities (Figure 
12). Although results showed improved survival rates in all mice treated with ROR1-
targeting CAR T cells (indicated as 2A2 ROR1 and R12 ROR1) and CD19-CAR T cells, 
R12 ROR1-CAR T cells demonstrated the highest mouse survival rate (Figure 12; 
Hudecek et al., 2013). Taken together, this in vivo study conferred tumor-recognition 
consistent with the in vitro studies previously discussed. This data suggests that a high 
affinity ROR1-CAR such as R12 is able to demonstrate a significant anti-tumor response, 
in vivo (Hudecek et al., 2013). 
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Figure 12. Survival rates of MCL mice treated with ROR1-CAR T cell therapy. 
Kaplan-Meier analysis shows the survival of immunodeficient mice inoculated with the 
human MCL line JeKo-1. Seven days post inoculation, mice were injected with ROR1-
CAR T cells of different affinities (indicated as 2A2 ROR1 and R12 ROR1), and 
compared to results from CD19-CAR T cells, truncated EGFR T-cells (control), and 
untreated mice. Improved survival was observed in all treated mice, with T cells 
expressing the R12 ROR1-CAR showing superior survival results. Taken from (Hudecek 
et al., 2013). 
 
While ROR1 is indeed a promising CAR T cell target in hematologic cancers, it 
has also shown to be effective in the context solid cancers. In this study, Huang et al. 
(2015) assessed ROR1-CAR T cell cytotoxicity against the osteosarcoma cell line 
SaOS2. In vitro results showed that ROR1-CAR T cells significantly destroyed ROR1+ 
SaOS2 cells, while ROR1- sarcoma cell lines were spared. Further analysis demonstrated 
that ROR1-CAR T cells derived from a healthy donor as well as sarcoma patients 
produced high levels of Th1 cytokines in response to antigen stimulation (Huang et al., 
2015). In vivo evidence showed significant tumor suppression in sarcoma xenografts, 
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particularly evident at days 14 and 21 (Huang et al., 2015). These results were consistent 
with data from the MCL mouse model previously described. 
Despite the in vitro and in vivo success of the T-cell therapy, the risk of on-
target/off-tumor toxicities warranted the need for further safety studies in a relevant 
model. Berger et al. (2015) determined that the macaca mulatta (rhesus macaque) and 
hROR1 homologues exhibited similar tissue expression, proposing that the non-human 
primate model would be sufficient in examining the safety for CAR-T cells. Although 
their data support the initial safety and efficacy of ROR1-CAR T cells in eliminating 
ROR1+ B cells, long-term safety trials will need to be examined.  
Currently, an ongoing phase 1 trial (clinicaltrials.gov, NCT02706392) is 
investigating the safety, effectiveness, and tolerability of CAR-T cell therapy in treating 
patients with advanced ROR1+ malignancies, including CLL, MCL, acute lymphoblastic 
leukemia (ALL), stage IV non-small cell lung cancer (NSCLC), and triple negative breast 
cancer (TNBC). 
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DISCUSSION 
 
Published data continues to support the therapeutic potential of cirmtuzumab in 
targeting ROR1+ malignancies. Although several anti-ROR1 mAbs have been developed, 
only cirmtuzumab has entered a phase I dose escalation trial in patients with relapsed or 
refractory CLL (clinicaltrials.gov, NCT02222688). The implications for cirmtuzumab 
extend beyond CLL, especially since the prevalence of ROR1 is largely restricted to 
embryogenesis and cancerous cells, and not their normal tissue counterparts (Zhang et al., 
2012). Current CLL literature focuses heavily on mAbs that target the cell surface protein 
CD20, an antigen also found on normal B cells, which enhances the potential for 
toxicities against non-malignant cells (Singh et al., 2018). Targeting ROR1 may be 
advantageous in treating B cell malignancies, given that ROR1 is primarily a tumor-
specific antigen, emphasizing the need for continued research. 
Efficacy, tolerability, and safety of cirmtuzumab were supported by animal 
models. Choi et al. (2015) assessed dose-dependent toxicities in rats and found 
cirmtuzumab to be well tolerated. This study also demonstrated that cynomolgus 
monkeys showed no adverse reactions to a constant dosage of cirmtuzumab, supporting 
the safety of targeting ROR1and encouraging further assessment in clinical human trials. 
However, there were some weaknesses with the data presented in this study that decrease 
the ability to interpret the link between cirmtuzumab treatment and off-target toxicities to 
normal tissues. In particular, samples from normal post-partum tissues probed with 
cirmtuzumab demonstrated no cross-reactivity, including the pancreas and adipose tissue. 
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This is contrary to the literature that has found ROR1 to be highly expressed in the 
parathyroid, pancreatic islets, and the gut, emphasizing the potential for off-tumor 
toxicity and the importance in detecting ROR1 presence in normal tissues (Balakrishnan 
et al., 2016). It is possible that cirmtuzumab, an anti-ROR1 mAb highly specific to the 
extracellular domain of ROR1, failed to detect endogenous levels of ROR1 in normal 
tissue, highlighting the challenge of ROR1-targeted cancer therapies. 
Although the presence of ROR1 in normal tissues remains a major concern for 
off-target toxicities, there is indisputable evidence that indicates the potential advantage 
of combination therapy. Ibrutinib, a BTK inhibitor used to treat MCL and CLL patients, 
has demonstrated to have an additive, if not synergistic response in patients when treated 
in combination with cirmtuzumab (Karvonen et al., 2017). In vivo treatment with both 
ibrutinib and cirmtuzumab was superior than either monotherapy in clearing CLL cells, 
indicating a major advantage that should be explored in a clinical context (Karvonen et 
al., 2017). Co-targeting ROR1 and the BCR pathway has also shown potential in the 
MCL model, as both share the downstream NF-κB target important to B-cell 
malignancies (Karvonen et al., 2017). Despite the clinical potential in combinatorial 
treatment, BTK inhibition has shown to cause down-regulation of ROR1 expression, 
which consequently impacts the effectiveness ROR1-targeted therapies (Karvonen et al., 
2017). Future research will need to carefully explore BCR- and ROR1-targeted drugs in 
other ROR1+ hematological cancers and clinical settings. Above all, cirmtuzumab has 
proven as an encouraging anti-ROR1 mAb, and should continue to be pursued in the 
context of other ROR1+ cancers. 
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As a cell-surface receptor highly expressed in malignant cells, ROR1 presents as 
an attractive target for ADC therapy. Given the strong affinity for ROR1 and high rate of 
internalization, cirmtuzumab in particular should continue to be explored as an ideal 
candidate for delivering a cytotoxic payload to targeted cells. Although data supports 
cirmtuzumab-ADC as a novel and promising treatment, it is important to highlight the 
potential of cytotoxicity to normal tissues expressing ROR1. Further characterization of 
ROR1 expression will be crucial to ensuring the safety of ADC treatment in clinical 
trials. 
Despite toxicity concerns, in vivo CLL xenographs supported the use of 
cirmtuzumab-MMAE in effectively eliminating malignant ROR1+ cells (Cui et al., 
2013). Analogous to the in vivo results, cirmtuzumab-MMAE also demonstrated in vitro 
success using adenocarcinoma cell lines of the breast and pancreas (Cui et al., 2013). As 
expected, ROR1- cell lines remained largely unaffected by the ADC therapy, warranting 
further research into the safety and tolerability of cirmtuzumab-ADC (Cui et al., 2013). 
Tests of CLL cell survival revealed that the anti-ROR1 mAb was particularly more 
effective in inducing CLL cell death then the non-ROR1 targeting mAb when conjugated 
to the OSU-2S drug (Mani et al., 2014). This, in conjunction with the greater rate of 
internalization and affinity for ROR1, suggests that utilizing mAbs that target ROR1 may 
be advantageous in ADC therapy compared to their non-ROR1 mAb counterparts (Mani 
et al., 2014). Future approaches should focus on maximizing the delivery of ADCs and 
extending this research to other ROR1+ malignancies. 
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Although ADCs present as a novel, highly potent targeting agent, improving the 
therapeutic index of the treatment in solid and hematologic tumors remains a challenge. 
To date, only 4 ADCs are approved by the American Food and Drug Administration, 
illustrating the difficulty in optimizing a safe and tolerable ADC therapy (Rossin et al., 
2018). For instance, the efficacy of ADC treatment and delivery of the cytotoxic payload 
is highly impacted by the cell surface density of the target antigen (Rossin et al., 2018). 
In contrast to solid tumors, hematologic tumors generally exhibit homogenous expression 
of the target antigen and are well perfused (Rossin et al., 2018). Thus, those antigens are 
more accessible to the antibodies circulating in the plasma. Solid tumor antigens are 
frequently heterogenous in nature, restricted in distribution, and demonstrate inefficient 
internalization kinetics, which ultimately impedes drug delivery (Rossin et al., 2018). 
ROR1-targeted ADC therapy, however, is particularly advantageous because the ROR1 
antigen is highly expressed on the surface of tumor cells rather than normal cells, which 
facilitates the site-specific delivery of a cytotoxic payload (Baskar et al., 2008). 
Additionally, homogenous ROR1 expression has been implicated in both hematologic 
and solid cancers such as triple-negative breast cancer, ovarian cancer, lung 
adenocarcinomas, which underlines the potential success for ADC therapy (Balakrishnan 
et al., 2016).   
As this field continues to rapidly evolve, it will be of interest to see how future 
modifications to ADC design will impact the next generation of ADCs. Cancer 
therapeutic resistance poses a very complex challenge for the development of better 
therapies, and the increasing prevalence of resistance necessitates the need to improve 
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understanding. Indeed, it will be crucial to focus research on optimizing current ADC 
design, as there may be incredible value in refining linker and conjugation chemistries in 
ADCs in order to significantly improve the delivery of the cytotoxic agent to the target 
cell.  
Although current therapeutics like cirmtuzumab and ROR1-targeted ADCs are 
focused on targeting the extracellular domain of ROR1 to suppress tumor growth, 
researchers have now shifted focus on targeting the intracellular TK domain of ROR1 to 
illicit a similar response. KAN0439834 is a novel SMI active against phosphorylated 
ROR1, which is directly associated with a progressive disease stage in hematological 
malignancies (Hojjat-Farsangi et al., 2013). In vitro studies showed that KAN0439834 
had a significant capacity for inducing the cell death of PC and CLL cell lines 
(Daneshmanesh et al., 2018). Similar to the cirmtuzumab combination therapies, 
KAN0439834 also exhibited an augmented effect when combined with kinase inhibitors 
(Daneshmanesh et al., 2018).  It is likely that the additive therapeutic results are due to 
the inhibitors different but complementary mechanisms of action in initiating apoptosis 
and tumor cell death. Taking advantage of combination treatments could provide the 
solution to overcoming drug resistance and increasing efficacy. Although it is difficult to 
compare the potency of KAN0439834 to the other ROR1 therapies discussed, especially 
given the use of different cell lines and sites of action, there is indisputable evidence 
suggesting the benefit of combination therapy with Ibrutinib. It will be of interest to 
continue to pursue and optimize KAN0439834 treatment in conjunction with Ibrutinib.    
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Analysis of protein levels demonstrated that KAN0439834 was able to completely 
dephosphorylate the TK domain of ROR1, and thus down-regulate ROR1 associated 
signaling molecules of the pro-survival PI3K/AKT/mTOR pathway (Hojjat-Farsangi et 
al., 2018). Moreover, both the PC and CLL cell lines observed ROR1/LRP6 
heterodimerization and consequent dephosphorylation when incubated with 
KAN0439834 (Hojjat-Farsangi et al., 2018). Interestingly, only the CLL cells 
demonstrated a dissociation between the ROR1/LRP6 complex when treated with 
KAN0439834, while no dissociation was observed in the PC cells. These results suggest 
that the initial apoptotic cascade event may differ between malignancies. Further analysis 
will be needed in order to fully understand the mechanisms involved in ROR1+ tumor cell 
death. Irrespective of the initial event, the PI3K/AKT/mTOR pathway remains crucial to 
the apoptotic cascade.  
Currently, the published literature on KAN0439834 is very limited. Although the 
presented data supports the use of KAN0439834 in inducing apoptosis, it will be of 
interest to explore the therapy across different cancer types in order to address any 
variability. Further investigation will be critical to understanding the potential for 
resistance, off-target toxicities, and mechanisms of action particularly in combination 
with other targeting agents.  
Previous clinical trials that have utilized CAR-modified T cells for B-cell 
malignancies focused primarily on the B-cell lineage antigens CD20 and CD19 (Jensen et 
al., 2010). However, targeting B-cell lineage antigens presents the risk of destroying 
normal mature B cells, which emphasizes the need to identify antigens with restricted 
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expression on malignant cells. By comparing the efficacy of the ROR1-CAR construct 
with the similarly designed CD20-CAR, Hudecek et al. (2010) demonstrated the 
advantage in ROR1-CAR T cells to selectively recognize and lyse CLL cells while 
sparing normal B cells. In addition to the in vitro studies, mouse and primate models also 
exhibited an increase in effector cytokines following the treatment of ROR1 CAR-T 
(Berger et al., 2015). However, as the magnitude of immune activation exceeds that of a 
natural setting, the concern for severe toxicities become imminent. A recent study by 
Fitzgerald et al. (2017), for instance, has warned clinicians of the potential for developing 
Cytokine Release Syndrome (CRS) following CAR-T treatment in acute lymphoblastic 
leukemia patients. CRS, characterized by high fevers, tachycardia, and organ 
dysfunction, is predicted to increase in disease burden as CAR-T therapy continues to 
expand into the clinical setting (Fitzgerald et al., 2017). CRS surveillance and treatment 
protocols will need to be standardized for future ROR1 CAR-T clinical trials, especially 
to ensure the safety of the participants while simultaneously maintaining treatment 
efficacy.  
Although the therapeutic results are encouraging, it is important to consider the 
possibility of toxicity to normal ROR1-expressing tissues.  The use of macaques for CAR 
treatment provided incredible preclinical insight, especially given the similarities between 
human and macaque ROR1 expression (Berger et al., 2015). Concerningly, the macaque 
study noted a minor lysis of healthy adipocytes following ROR1 CAR-T cell treatment, 
suggesting the potential for damage to normal tissues (Berger et al., 2015). Despite a lack 
of overt toxicity or weight loss, this reemphasizes the need to characterize ROR1 
 41 
expression adequately. It would be of interest for future studies to focus on whether the 
level of ROR1 expression is linked to T cell migration, especially because it is unclear if 
the low level of ROR1 in adipose tissue was sufficient enough to cause damage by ROR1 
CAR-T cells. Nevertheless, nonhuman primate models are pivotal to determining the 
safety and efficacy of ROR1-targeted therapies, and should continue to be implemented 
in future ROR1 research.  
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CONCLUSION 
 
 The literature data examined in this review supports ROR1 as a potential 
target for the development of anti-cancer therapies. As an oncofetal protein highly 
implicated with tumor cell growth and survival, ROR1 may serve as a clinical biomarker 
for patient outcome. Despite the encouraging results of ROR1-targeted therapies, the 
potential for on-target, off-tumor toxicities remain a critical concern. Earlier studies that 
have analyzed ROR1 expression have reported that ROR1 is absent in most normal 
tissues (Baskar et al., 2008; Zhang et al., 2014). However, more recent studies have 
proposed that ROR1 is expressed in normal parathyroid, pancreatic islets, adipocytes and 
regions of the gastrointestinal tracts (Balakrishnan et al., 2016). These contradicting 
reports provide a rationale for further investigation in order to improve long-term 
toxicities associated with current treatment strategies. Currently, the role of ROR1 in 
normal adult tissues is not well understood, and the mechanism and timing of ROR1 re-
expression in oncogenesis is still unknown. A deeper understanding of the ROR1 
signaling pathways will be crucial to optimizing current therapeutic strategies. It will be 
of particular interest to focus research on elucidating the tumor-specific mechanisms of 
ROR1 upregulation in order to effectively develop and utilize ROR1-targeting therapies.  
These presented studies warrant future research into the characterization of ROR1 in 
normal tissues and its function in tumor progression, prognosis, and therapy. 
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